A Randomized Comparison of Pulmonary Vein Isolation With Versus Without Concomitant Renal Artery Denervation in Patients With Refractory Symptomatic Atrial Fibrillation and Resistant Hypertension

被引:356
作者
Pokushalov, Evgeny [1 ]
Romanov, Alexander
Corbucci, Giorgio [2 ]
Artyomenko, Sergey
Baranova, Vera
Turov, Alex
Shirokova, Natalya
Karaskov, Alexander
Mittal, Suneet [3 ,4 ]
Steinberg, Jonathan S. [3 ,4 ]
机构
[1] State Res Inst Circulat Pathol, Arrhythmia Dept, Novosibirsk 30055 55, Russia
[2] Medtron BRC, Maastricht, Netherlands
[3] Valley Hlth Syst, New York, NY USA
[4] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA
关键词
ablation; atrial fibrillation; renal denervation; resistant hypertension; RISK-FACTORS; SYMPATHETIC DENERVATION; FOLLOW-UP; PREDICTORS; COMMITTEE; PROGNOSIS; ABLATION;
D O I
10.1016/j.jacc.2012.05.036
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The aim of this prospective randomized study was to assess the impact of renal artery denervation in patients with a history of refractory atrial fibrillation (AF) and drug-resistant hypertension who were referred for pulmonary vein isolation (PVI). Background Hypertension is the most common cardiovascular condition responsible for the development and maintenance of AF. Treating drug-resistant hypertension with renal denervation has been reported to control blood pressure, but any effect on AF is unknown. Methods Patients with a history of symptomatic paroxysmal or persistent AF refractory to >= 2 antiarrhythmic drugs and drug-resistant hypertension (systolic blood pressure >160 mm Hg despite triple drug therapy) were eligible for enrolment. Consenting patients were randomized to PVI only or PVI with renal artery denervation. All patients were followed >= 1 year to assess maintenance of sinus rhythm and to monitor changes in blood pressure. Results Twenty-seven patients were enrolled, and 14 were randomized to PVI only, and 13 were randomized to PVI with renal artery denervation. At the end of the follow-up, significant reductions in systolic (from 181 +/- 7 to 156 +/- 5, p < 0.001) and diastolic blood pressure (from 97 +/- 6 to 87 +/- 4, p < 0.001) were observed in patients treated with PVI with renal denervation without significant change in the PVI only group. Nine of the 13 patients (69%) treated with PVI with renal denervation were AF-free at the 12-month post-ablation follow-up examination versus 4 (29%) of the 14 patients in the PVI-only group (p = 0.033). Conclusions Renal artery denervation reduces systolic and diastolic blood pressure in patients with drug-resistant hypertension and reduces AF recurrences when combined with PVI. (Combined Treatment of Resistant Hypertension and Atrial Fibrillation; NCT01117025) (J Am Coll Cardiol 2012; 60: 1163-70) (C) 2012 by the American College of Cardiology Foundation
引用
收藏
页码:1163 / 1170
页数:8
相关论文
共 23 条
  • [1] Impact of atrial fibrillation on the risk of death
    Benjamin, EJ
    Wolf, PA
    D'Agostino, RB
    Silbershatz, H
    Kannel, WB
    Levy, D
    [J]. CIRCULATION, 1998, 98 (10) : 946 - 952
  • [2] INDEPENDENT RISK-FACTORS FOR ATRIAL-FIBRILLATION IN A POPULATION-BASED COHORT - THE FRAMINGHAM HEART-STUDY
    BENJAMIN, EJ
    LEVY, D
    VAZIRI, SM
    DAGOSTINO, RB
    BELANGER, AJ
    WOLF, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (11): : 840 - 844
  • [3] Resistant hypertension: Diagnosis, evaluation, and treatment - A Scientific Statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research
    Calhoun, David A.
    Jones, Daniel
    Textor, Stephen
    Goff, David C.
    Murphy, Timothy P.
    Toto, Robert D.
    White, Anthony
    Cushman, William C.
    White, William
    Sica, Domenic
    Ferdinand, Keith
    Giles, Thomas D.
    Falkner, Bonita
    Carey, Robert M.
    [J]. HYPERTENSION, 2008, 51 (06) : 1403 - 1419
  • [4] Disertori M, 2009, NEW ENGL J MED, V360, P1606, DOI 10.1056/NEJMoa0805710
  • [5] Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
    Esler, Murray D.
    Krum, Henry
    Sobotka, Paul A.
    Schlaich, Markus P.
    Schmieder, Roland E.
    Boehm, Michael
    Mahfoud, Felix
    Sievert, Horst
    Wunderlich, Nina
    Rump, Lars Christian
    Vonend, Oliver
    Uder, Michael
    Lobo, Mel
    Caulfield, Mark
    Erglis, Andrejs
    Azizi, Michel
    Sapoval, Marc
    Thambar, Suku
    Persu, Alexandre
    Renkin, Jean
    Schunkert, Heribert
    Weil, Joachim
    Hoppe, Uta C.
    Walton, Tony
    Scheinert, Dierk
    Binder, Thomas
    Januszewicz, Andrzej
    Witkowski, Adam
    Ruilope, Luis M.
    Whitbourn, Robert
    Bruck, Heike
    Downes, Mark
    Luescher, Thomas F.
    Jardine, Alan G.
    Webster, Mark W.
    Zeller, Thomas
    Sadowski, Jerzy
    Bartus, Krzysztof
    Straley, Craig A.
    Barman, Neil C.
    Lee, David P.
    Witteles, Ronald M.
    Bhalla, Vivek
    Massaro, Joseph M.
    [J]. LANCET, 2010, 376 (9756) : 1903 - 1909
  • [6] Gewirtz JR, 2011, CARDIOL J, V18, P97
  • [8] Huxley RR, 2011, CIRCULATION, V123, P1501, DOI [10.1161/CIRCULATIONAHA.110.009035, 10.1161/circulationaha.110.009035]
  • [9] Prevalence, Predictors, and Prognosis of Atrial Fibrillation Early After Pulmonary Vein Isolation: Findings from 3 Months of Continuous Automatic ECG Loop Recordings
    Joshi, Sandeep
    Choi, Andrew D.
    Kamath, Ganesh S.
    Raiszadeh, Farbod
    Marrero, Daniel
    Badheka, Apurva
    Mittal, Suneet
    Steinberg, Jonathan S.
    [J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2009, 20 (10) : 1089 - 1094
  • [10] THE NATURAL-HISTORY OF ATRIAL-FIBRILLATION - INCIDENCE, RISK-FACTORS, AND PROGNOSIS IN THE MANITOBA FOLLOW-UP-STUDY
    KRAHN, AD
    MANFREDA, J
    TATE, RB
    MATHEWSON, FAL
    CUDDY, TE
    [J]. AMERICAN JOURNAL OF MEDICINE, 1995, 98 (05) : 476 - 484